{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T18:20:09Z","timestamp":1773512409496,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117414","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:28Z","timestamp":1760108848000},"page":"117414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P4","title":["Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors"],"prefix":"10.1016","volume":"242","author":[{"given":"Amanda M.","family":"Kozarich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit U.","family":"Katti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gershon A.K.","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-3234","authenticated-orcid":false,"given":"Michael G.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117414_b0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.biochem.71.102301.093055","article-title":"Mammalian ABC transporters in health and disease","volume":"71","author":"Borst","year":"2002","journal-title":"Annu. Rev. Biochem"},{"issue":"5922","key":"10.1016\/j.bcp.2025.117414_b0010","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science (New York, N.Y.)"},{"issue":"47","key":"10.1016\/j.bcp.2025.117414_b0015","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2025.117414_b0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-Glycoprotein, a gatekeeper in the blood\u2013brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"21","key":"10.1016\/j.bcp.2025.117414_b0030","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":"Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117414_b0035","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bcp.14178","article-title":"Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours","volume":"86","author":"Elmeliegy","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117414_b0040","unstructured":"FDA, 2024. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers. FDA; FDA. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers."},{"key":"10.1016\/j.bcp.2025.117414_b0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcp.2025.117414_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00265","article-title":"Perplexing role of P-glycoprotein in tumor microenvironment","volume":"10","author":"Robinson","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics","volume":"42","author":"Lin","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.bcp.2025.117414_b0060","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117414_b0065","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-1-60761-416-6_21","article-title":"Circumventing tumor resistance to chemotherapy by nanotechnology","volume":"596","author":"Liang","year":"2010","journal-title":"Methods Mol. Biol. (Clifton N.J.)"},{"issue":"2","key":"10.1016\/j.bcp.2025.117414_b0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"J. Pathol."},{"issue":"15","key":"10.1016\/j.bcp.2025.117414_b0075","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.3390\/ijms23158412","article-title":"PARP inhibitors: clinical limitations and recent attempts to overcome them","volume":"23","author":"Kim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2011.03.020","article-title":"Genetic interactions in cancer progression and treatment","volume":"145","author":"Ashworth","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2025.117414_b0090","first-page":"608","article-title":"Mechanisms of resistance to PARP inhibitors\u2014an evolving challenge in oncology","volume":"2","author":"Mweempwa","year":"2019","journal-title":"Cancer Drug Resistance"},{"issue":"21","key":"10.1016\/j.bcp.2025.117414_b0095","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117414_b0100","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.molcel.2015.05.007","article-title":"Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-ribosylation","volume":"58","author":"Barkauskaite","year":"2015","journal-title":"Mol. Cell"},{"issue":"Pt 2","key":"10.1016\/j.bcp.2025.117414_b0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj3420249","article-title":"Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions","volume":"342","author":"D\u2019Amours","year":"1999","journal-title":"Biochem. J"},{"issue":"7","key":"10.1016\/j.bcp.2025.117414_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/nrm3376","article-title":"New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs","volume":"13","author":"Gibson","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117414_b0115","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.molcel.2015.06.001","article-title":"SnapShot: ADP-ribosylation signaling","volume":"58","author":"Hottiger","year":"2015","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.bcp.2025.117414_b0120","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.6b00990","article-title":"Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors","volume":"60","author":"Thorsell","year":"2017","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2025.117414_b0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117414_b0130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7035","key":"10.1016\/j.bcp.2025.117414_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117414_b0140","unstructured":"Clinical Trials Using Olaparib\u2014NCI (nciglobal,ncienterprise). (n.d.). [nciAppModulePage]. Retrieved June 12, 2025, from https:\/\/www.cancer.gov\/research\/participate\/clinical-trials\/intervention\/olaparib?pn=1."},{"key":"10.1016\/j.bcp.2025.117414_b0145","unstructured":"Clinical Trials Using Talazoparib\u2014NCI (nciglobal,ncienterprise). (n.d.). [nciAppModulePage]. Retrieved June 12, 2025, from https:\/\/www.cancer.gov\/research\/participate\/clinical-trials\/intervention\/talazoparib?pn=1."},{"issue":"5","key":"10.1016\/j.bcp.2025.117414_b0150","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11912-025-01669-z","article-title":"PARP inhibitors in the neoadjuvant setting; a comprehensive overview of the rationale for their use, past and ongoing clinical trials","volume":"27","author":"Habaka","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bcp.2025.117414_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113580","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): final overall survival results from a randomized phase 3 trial","volume":"200","author":"Di\u00e9ras","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2025.117414_b0160","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2025.117414_b0165","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2147\/OTT.S69935","article-title":"Profile of veliparib and its potential in the treatment of solid tumors","volume":"8","author":"Wagner","year":"2015","journal-title":"OncoTargets and Therapy"},{"issue":"10","key":"10.1016\/j.bcp.2025.117414_b0170","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.bcp.2025.117414_b0175","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e86","article-title":"Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective","volume":"33","author":"Li","year":"2022","journal-title":"J. Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117414_b0180","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","article-title":"Pamiparib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2025.117414_b0185","unstructured":"Center for Drug Evaluation and Research, 2014. Clinical pharmacology and biopharmaceutics review(s)\u2014Olaparib (No. 3663410). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206162Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.bcp.2025.117414_b0190","unstructured":"Center for Drug Evaluation and Research, 2016. Multi-discipline review: Executive Summary; Nonclinical Pharmacology\/Toxicology; Clinical Pharmacology; Statistical and Clinical Evaluation\u2014Niraparib (No. 4074987)."},{"key":"10.1016\/j.bcp.2025.117414_b0195","unstructured":"Center for Drug Evaluation and Research, 2016. Multi-discipline review Summary \/ Clinical \/ Non-Clinical\u2014Rucaparib (No. 4017830). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209115Orig1s000MultiDisciplineR.pdf."},{"key":"10.1016\/j.bcp.2025.117414_b0200","article-title":"PARP inhibitors: Enhancing efficacy through rational combinations","volume":"1\u201313","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2025.117414_b0205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: Overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bcp.2025.117414_b0210","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.7150\/ijbs.41395","article-title":"Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging","volume":"16","author":"Morosi","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"7553","key":"10.1016\/j.bcp.2025.117414_b0215","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"44","key":"10.1016\/j.bcp.2025.117414_b0220","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2025.117414_b0225","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","article-title":"Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug\u2013drug interaction studies","volume":"59","author":"Elmeliegy","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.bcp.2025.117414_b0230","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/ol.2023.13747","article-title":"Transporter\u2011mediated drug\u2011drug interactions involving poly (ADP\u2011ribose) polymerase inhibitors (Review)","volume":"25","author":"Zhao","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2025.117414_b0235","unstructured":"U.S. Department of Health and Human Services, U.S. Food and Drug Administration, & Center for Drug Evaluation and Research, 2020. In vitro drug interaction studies: Cytochrome P-450 enzyme- and transporter-mediated drug interactions [Guidance for Industry]. National Library of Medicine. https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-101767646-pdf."},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11095-014-1442-z","article-title":"Breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699)","volume":"32","author":"Durmus","year":"2015","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.bcp.2025.117414_b0245","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1021\/acs.molpharmaceut.1c00553","article-title":"P-glycoprotein (ABCB1\/MDR1) controls brain penetration and intestinal disposition of the PARP1\/2 inhibitor niraparib","volume":"18","author":"Martins","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2025.117414_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106177","article-title":"Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice","volume":"173","author":"Song","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2025.117414_b0255","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-17-0365","article-title":"Restricted delivery of talazoparib across the blood\u2013brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma","volume":"16","author":"Kizilbash","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117414_b0260","doi-asserted-by":"crossref","first-page":"34711","DOI":"10.1074\/jbc.274.49.34711","article-title":"Large scale purification of detergent-soluble P-glycoprotein from Pichia pastoris cells and characterization of nucleotide binding properties of wild-type, walker a, and walker B mutant proteins","volume":"274","author":"Lerner-Marmarosh","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"51","key":"10.1016\/j.bcp.2025.117414_b0265","doi-asserted-by":"crossref","first-page":"13686","DOI":"10.1021\/bi801409r","article-title":"Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport","volume":"47","author":"Eckford","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2025.117414_b0270","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bcp.2016.08.013","article-title":"Cooperativity between verapamil and ATP bound to the efflux transporter P-glycoprotein","volume":"118","author":"Ledwitch","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0003-2697(88)90002-4","article-title":"A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases","volume":"168","author":"Chifflet","year":"1988","journal-title":"Anal. Biochem."},{"issue":"22","key":"10.1016\/j.bcp.2025.117414_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216058","article-title":"Drug-induced conformational dynamics of P-glycoprotein underlies the transport of camptothecin analogs","volume":"24","author":"Mensah","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117414_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113813","article-title":"The effects of anthracycline drugs on the conformational distribution of mouse P-glycoprotein explains their transport rate differences","volume":"174","author":"Nguyen","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117414_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103708","article-title":"Insights into interactions between taxanes and P-glycoprotein using biophysical and in silico methods","volume":"114","author":"Xu","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2025.117414_b0295","series-title":"Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems","author":"Segel","year":"1993"},{"key":"10.1016\/j.bcp.2025.117414_b0300","series-title":"Membrane Transporters: Methods and Protocols","first-page":"109","article-title":"Fluorescence Techniques for Studying Membrane Transport Proteins","author":"Sharom","year":"2003"},{"issue":"11","key":"10.1016\/j.bcp.2025.117414_b0305","doi-asserted-by":"crossref","first-page":"e3253","DOI":"10.21769\/BioProtoc.3253","article-title":"Tryptophan fluorescence quenching assays for measuring protein-ligand binding affinities: principles and a practical guide","volume":"9","author":"Yammine","year":"2019","journal-title":"Bio-Protocol"},{"key":"10.1016\/j.bcp.2025.117414_b0310","series-title":"Principles of Fluorescence Spectroscopy","author":"Lakowics","year":"2010"},{"issue":"7","key":"10.1016\/j.bcp.2025.117414_b0315","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.xphs.2018.02.019","article-title":"A conformationally gated model of methadone and loperamide transport by P-glycoprotein","volume":"107","author":"Gibbs","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2025.117414_b0320","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.xphs.2017.02.032","article-title":"Insights into the molecular mechanism of triptan transport by P-glycoprotein","volume":"106","author":"Wilt","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"45","key":"10.1016\/j.bcp.2025.117414_b0325","doi-asserted-by":"crossref","first-page":"11749","DOI":"10.1021\/ja9820543","article-title":"Acrylamide quenching of protein phosphorescence as a monitor of structural fluctuations in the globular fold","volume":"120","author":"Cioni","year":"1998","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.bcp.2025.117414_b0330","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/jp909567q","article-title":"Fluorescence quenching of buried Trp residues by acrylamide does not require penetration of the protein fold","volume":"114","author":"Strambini","year":"2010","journal-title":"J. Phys. Chem. B"},{"issue":"12","key":"10.1016\/j.bcp.2025.117414_b0335","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1021\/bi101797v","article-title":"NMR-derived models of amidopyrine and its metabolites in complexes with rabbit cytochrome P450 2B4 reveal a structural mechanism of sequential N-dealkylation","volume":"50","author":"Roberts","year":"2011","journal-title":"Biochemistry"},{"issue":"7","key":"10.1016\/j.bcp.2025.117414_b0340","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1021\/ed101169t","article-title":"Saturation-transfer difference (STD) NMR: a simple and fast method for ligand screening and characterization of protein binding","volume":"88","author":"Viegas","year":"2011","journal-title":"J. Chem. Educ."},{"issue":"7","key":"10.1016\/j.bcp.2025.117414_b0345","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1021\/acsmacrolett.1c00270","article-title":"Saturation transfer difference NMR spectroscopy for the elucidation of supramolecular albumin\u2013polymer interactions","volume":"10","author":"Xu","year":"2021","journal-title":"ACS Macro Lett."},{"key":"10.1016\/j.bcp.2025.117414_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00041","article-title":"Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function","volume":"4","author":"Sharom","year":"2014","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0355","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/jmre.1998.1405","article-title":"Improved WATERGATE pulse sequences for solvent suppression in NMR spectroscopy","volume":"132","author":"Liu","year":"1998","journal-title":"J. Magn. Reson."},{"issue":"6","key":"10.1016\/j.bcp.2025.117414_b0360","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/BF02192855","article-title":"Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions","volume":"2","author":"Piotto","year":"1992","journal-title":"J. Biomol. NMR"},{"issue":"8","key":"10.1016\/j.bcp.2025.117414_b0365","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13081146","article-title":"A bidirectional permeability assay for beyond rule of 5 compounds","volume":"13","author":"Cui","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0370","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12987-023-00495-4","article-title":"Application of a new MDCKII-MDR1 cell model to measure the extent of drug distribution in vitro at equilibrium for prediction of in vivo unbound brain-to-plasma drug distribution","volume":"21","author":"Langthaler","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.bcp.2025.117414_b0375","unstructured":"MTT assay protocol | Abcam. (n.d.). Retrieved June 23, 2025, from https:\/\/www.abcam.com\/en-us\/technical-resources\/protocols\/mtt-assay."},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0380","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.MCT-06-0155","article-title":"About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work","volume":"6","author":"Sauna","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117414_b0385","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0925-4439(97)00026-4","article-title":"Structure-activity relationships of P-glycoprotein interacting drugs: Kinetic characterization of their effects on ATPase activity","volume":"1361","author":"Litman","year":"1997","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.bcp.2025.117414_b0390","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.576559","article-title":"P-glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers","volume":"10","author":"Seelig","year":"2020","journal-title":"Front. Oncol."},{"issue":"52","key":"10.1016\/j.bcp.2025.117414_b0395","doi-asserted-by":"crossref","first-page":"52629","DOI":"10.1074\/jbc.M308175200","article-title":"Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein*","volume":"278","author":"Al-Shawi","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2025.117414_b0400","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1021\/bi051380+","article-title":"Quantification and characterization of P-glycoprotein\u2212substrate interactions","volume":"45","author":"Gatlik-Landwojtowicz","year":"2006","journal-title":"Biochemistry"},{"issue":"7421","key":"10.1016\/j.bcp.2025.117414_b0405","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature11448","article-title":"Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans","volume":"490","author":"Jin","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bcp.2025.117414_b0410","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.xphs.2024.03.014","article-title":"Probing the mechanisms underlying the transport of the vinca alkaloids by P-glycoprotein","volume":"113","author":"Mensah","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2025.117414_b0415","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1074\/jbc.M010044200","article-title":"Correlation between Steady-state ATP Hydrolysis and Vanadate-induced ADP Trapping in Human P-glycoprotein: evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates *","volume":"276","author":"Kerr","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2025.117414_b0420","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.bpj.2012.02.018","article-title":"P-glycoprotein-ATPase modulation: the molecular mechanisms","volume":"102","author":"Li-Blatter","year":"2012","journal-title":"Biophys. J."},{"issue":"4","key":"10.1016\/j.bcp.2025.117414_b0425","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0022-5193(05)80631-9","article-title":"Study of the relationship between estimates of enzyme kinetic parameters","volume":"155","author":"Wang","year":"1992","journal-title":"J. Theor. Biol."},{"issue":"23","key":"10.1016\/j.bcp.2025.117414_b0430","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem. Pharmacol."},{"issue":"25","key":"10.1016\/j.bcp.2025.117414_b0435","doi-asserted-by":"crossref","first-page":"17649","DOI":"10.1074\/jbc.274.25.17649","article-title":"Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein: a tryptophan fluorescence quenching analysis*","volume":"274","author":"Sonveaux","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"50","key":"10.1016\/j.bcp.2025.117414_b0440","doi-asserted-by":"crossref","first-page":"20412","DOI":"10.1074\/jbc.M117.814186","article-title":"Substrate-induced conformational changes in the nucleotide-binding domains of lipid bilayer\u2013associated P-glycoprotein during ATP hydrolysis","volume":"292","author":"Zoghbi","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2025.117414_b0445","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10863-016-9653-0","article-title":"Tryptophan fluorescence quenching as a binding assay to monitor protein conformation changes in the membrane of intact mitochondria","volume":"48","author":"Akbar","year":"2016","journal-title":"J. Bioenerg. Biomembr."},{"issue":"48","key":"10.1016\/j.bcp.2025.117414_b0450","doi-asserted-by":"crossref","first-page":"14927","DOI":"10.1021\/bi0018786","article-title":"Intrinsic fluorescence of the P-glycoprotein multidrug transporter: sensitivity of tryptophan residues to binding of drugs and nucleotides","volume":"39","author":"Liu","year":"2000","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.bcp.2025.117414_b0455","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bmb.2002.494030030035","article-title":"Protein tryptophan accessibility studied by fluorescence quenching","volume":"30","author":"M\u00f6ller","year":"2002","journal-title":"Biochem. Mol. Biol. Educ."},{"issue":"25","key":"10.1016\/j.bcp.2025.117414_b0460","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1021\/ja0100120","article-title":"Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor","volume":"123","author":"Mayer","year":"2001","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.bcp.2025.117414_b0465","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/jps.23901","article-title":"Establishment of optimized MDCK cell lines for reliable efflux transport studies","volume":"103","author":"Gartzke","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2025.117414_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100681","article-title":"Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update","volume":"49","author":"Dong","year":"2020","journal-title":"Drug Resist. Updat."},{"issue":"5","key":"10.1016\/j.bcp.2025.117414_b0475","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.8-5-411","article-title":"The role of ABC transporters in clinical practice","volume":"8","author":"Leonard","year":"2003","journal-title":"Oncologist"},{"issue":"20","key":"10.1016\/j.bcp.2025.117414_b0480","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2010-09-304311","article-title":"Dismounting the MDR horse","volume":"116","author":"Libby","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2025.117414_b0485","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO.1987.5.4.641","article-title":"Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients","volume":"5","author":"Ozols","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.117414_b0490","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1139\/o06-199","article-title":"Shedding light on drug transport: Structure and function of the P-glycoprotein multidrug transporter (ABCB1)","volume":"84","author":"Sharom","year":"2006","journal-title":"Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0495","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/s41598-020-59074-4","article-title":"The kinase polypharmacology landscape of clinical PARP inhibitors","volume":"10","author":"Antolin","year":"2020","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bcp.2025.117414_b0500","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1021\/jm100012m","article-title":"Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic","volume":"53","author":"Ferraris","year":"2010","journal-title":"J. Med. Chem."},{"issue":"34","key":"10.1016\/j.bcp.2025.117414_b0505","doi-asserted-by":"crossref","first-page":"21160","DOI":"10.1074\/jbc.272.34.21160","article-title":"Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein *","volume":"272","author":"Ambudkar","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2025.117414_b0510","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1007\/s00204-021-03115-y","article-title":"Differences in P-glycoprotein activity in human and rodent blood\u2013brain barrier assessed by mechanistic modelling","volume":"95","author":"Verscheijden","year":"2021","journal-title":"Arch. Toxicol."},{"issue":"15","key":"10.1016\/j.bcp.2025.117414_b0515","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1074\/jbc.RA119.012042","article-title":"In vivo FRET analyses reveal a role of ATP hydrolysis\u2013associated conformational changes in human P-glycoprotein","volume":"295","author":"Futamata","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2025.117414_b0520","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/bi401280v","article-title":"Reaction dynamics of ATP hydrolysis catalyzed by P-glycoprotein","volume":"53","author":"Scian","year":"2014","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.bcp.2025.117414_b0525","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121979119","article-title":"Inhibitors of PARP: number crunching and structure gazing","volume":"119","author":"Rudolph","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2025.117414_b0530","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1124\/dmd.110.037820","article-title":"Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase","volume":"39","author":"Li","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"25","key":"10.1016\/j.bcp.2025.117414_b0535","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2025.117414_b0540","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016573","article-title":"Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1","volume":"296","author":"Ryan","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"6486","key":"10.1016\/j.bcp.2025.117414_b0545","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax6367","article-title":"Structural basis for allosteric PARP-1 retention on DNA breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.bcp.2025.117414_b0550","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","article-title":"Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors","volume":"13","author":"Hopkins","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117414_b0555","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41467-021-20998-8","article-title":"Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs","volume":"12","author":"Rudolph","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:34:19Z","timestamp":1769477659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":111,"alternative-id":["S0006295225006793"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117414","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117414"}}